(Q43099284)

13 November 2017

title

Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease (English)

1 reference

13 November 2017

0 references

2

Jeffrey L Cummings

1 reference

13 November 2017

1

Martin R Farlow

1 reference

13 November 2017

Jason T Olin

3

1 reference

13 November 2017

Xiangyi Meng

series ordinal

4

1 reference

13 November 2017

language of work or name

English

0 references

publication date

14 April 2010

1 reference

American Journal of Alzheimer's Disease & Other Dementias

13 November 2017

published in

1 reference

13 November 2017

volume

25

1 reference

13 November 2017

issue

4

1 reference

13 November 2017

page(s)

347-352

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Memory performance is related to amyloid and tau pathology in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317510365344

21 January 2018

Identifiers

DOI

10.1177/1533317510365344

1 reference

13 November 2017

1 reference